Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 11/20 | 0.59 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19922870 | 0.99 | GCGR (0.58) | GCGRP2RY14SLC6A2 | |
| SCHEMBL19922788 | 0.93 | GCGR (0.61) | GCGRP2RY14SLC6A2 | |
| SCHEMBL19923021 | 0.89 | GCGR (0.55) | GCGR | |
| SCHEMBL19922907 | 0.89 | GCGR (0.65) | GCGRP2RY14SLC6A2 | |
| SCHEMBL19922811 | 0.88 | GCGR (0.78) | GCGR | |
| SCHEMBL19940304 | 0.88 | GCGR (0.59) | GCGRP2RY14SLC6A2 | |
| SCHEMBL19940302 | 0.87 | GCGR (0.45) | GCGR | |
| SCHEMBL19922764 | 0.87 | GCGR (0.77) | GCGR | |
| SCHEMBL19922864 | 0.86 | GCGR (0.57) | GCGRP2RY14SLC6A2 | |
| SCHEMBL19922869 | 0.83 | GCGR (0.64) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510022-B1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-05 | — | — | EP | disclosed |
| EP-3510022-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | Janssen Pharmaceutica NV (BE) | 2019-07-17 | — | — | EP | disclosed |
| US-10251864-B2 | Indole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-09 | — | — | US | disclosed |
| US-10251864-B2 | Indole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-09 | — | — | US | disclosed |
| WO-2018048761-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | WO | disclosed |
| US-20180064686-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-20180064686-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-20180064686-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251864-B2 | Indole derivatives useful as glucagon receptor antagonists | GPR119, GIPR, GLP1R | GCGR 4/4885P2RY14 1249/4885SLC6A2 738/4885 |
| US-20180064686-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GIPR, GLP1R | GCGR 4/4885P2RY14 1249/4885SLC6A2 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.